Dogecoin Cash, Inc.: Form 10-K for the period ended Dec 31, 2025
Filed with the SEC on Mar 27, 2026 and accepted by EDGAR at Mar 27, 2026, 16:20 ET.
Business
As filed, 7,733 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Overview
Dogecoin Cash, Inc. (the “Company”), formerly Cannabis Sativa, Inc. and previously Ultra Sun Corporation, was incorporated under the laws of the State of Nevada in November 2004.
The Company currently conducts its principal operations through its majority-owned subsidiary PrestoCorp, Inc., doing business as PrestoDoctor, which operates a telemedicine platform that connects patients with licensed physicians who conduct medical cannabis evaluations through secure video consultations in jurisdictions where such services are permitted under applicable state laws.
The Company provides the technology platform and administrative support that facilitate telemedicine consultations between patients and licensed physicians. The physicians who conduct medical cannabis evaluations through the PrestoDoctor platform are independent medical professionals who are responsible for the medical services they provide to patients in accordance with applicable state laws and professional standards.
The Company’s primary operating activity is the provision of telemedicine services through the PrestoDoctor platform. References to digital assets or related technology initiatives relate to exploratory or ancillary activities conducted through subsidiaries and do not represent the Company’s principal source of revenue.
The Company is not affiliated with, endorsed by, or otherwise associated with the cryptocurrency known as “Dogecoin” or any related digital asset project, and the Company does not issue or sponsor any cryptocurrency.
Business Model
The Company operates a technology-enabled telemedicine platform that facilitates medical cannabis evaluations conducted by licensed physicians where permitted by applicable state laws.
Patients schedule consultations through the PrestoDoctor platform and are connected with licensed physicians who conduct telemedicine consultations remotely using secure online technology.
The Company generates substantially all of its revenue from telemedicine consultation services facilitated through the PrestoDoctor platform.
Asset-Light Platform Model
The Company operates using an asset-light platform model in which telemedicine services are facilitated through digital infrastructure rather than through ownership of physical clinic locations or healthcare facilities.
The PrestoDoctor platform connects patients with licensed physicians through secure proprietary online technology, enabling telemedicine consultations to occur remotely in jurisdictions where permitted by applicable state laws.
Corporate Strategy
The Company’s strategy is to continue expanding its telemedicine platform while maintaining a capital-efficient operating structure.
The Company also maintains intellectual property assets and evaluates technology initiatives through subsidiaries including Dogecoin Treasury Inc., Dogespac LLC, and Meme Coins Inc.
Intellectual Property
The Company maintains cannabis-related intellectual property through Kubby Patent and Licenses, LLC.
This intellectual property includes:
- the Ecuadorian Sativa cannabis strain plant patent (CTA)
- a patent relating to a method of treating hypertension using a cannabinoid-containing lozenge delivery system.
While the Company maintains certain cannabis-related intellectual property assets, substantially all current revenues are generated from telemedicine consultation services facilitated through the PrestoDoctor platform.
Corporate Structure
The Company conducts its operations through a combination of operating and strategic subsidiaries.
Operating Subsidiary
- PrestoCorp, Inc. – telemedicine services conducted through the PrestoDoctor platform.
Strategic and Technology Subsidiaries
- Dogecoin Treasury, Inc. – technology initiative and digital asset treasury activities
- DogeSPAC LLC – digital asset acquisition entity
- Meme Coins, Inc. – digital asset investment subsidiary
Other Subsidiaries
- Kubby Patent and Licenses, LLC – intellectual property
- Eden Holdings LLC – trademark holdings
- Wild Earth Naturals, Inc. – inactive subsidiary
- Hi Brands International, Inc. – inactive subsidiary
Certain subsidiaries, including DogeSPAC LLC, Meme Coins, Inc., and Dogecoin Treasury, Inc., support the Company’s digital asset acquisition, investment, and treasury management initiatives.
Operating Segments
The Company currently operates primarily through a single reportable operating segment consisting of telemedicine services conducted through PrestoCorp, Inc.
Facilities
The Company maintains its principal executive office at:
355 West Mesquite Boulevard
Suite C70
Mesquite, Nevada 89027
The office space is utilized pursuant to a rental arrangement.
Many administrative functions of the Company are conducted remotely.
PrestoCorp, Inc. maintains office space in New York used for operational and administrative support.
The office space is utilized pursuant to a month-to-month rental arrangement.
Competition
The Company competes with other telemedicine platforms and healthcare technology providers offering remote consultation services.
Many competitors may have greater financial resources, larger physician networks, and more extensive technology infrastructure.
Government Regulation
Telemedicine services are subject to federal and state laws governing healthcare delivery, telemedicine practice, and patient privacy.
The physicians who conduct consultations through the PrestoDoctor platform are responsible for complying with applicable professional licensing and regulatory requirements.
Telemedicine services in the United States are subject to federal and state laws and regulations governing healthcare services, telemedicine practice, and the protection of patient information. These laws and regulations may include state licensing requirements applicable to physicians, telehealth practice standards, and privacy and data protection laws such as the Health Insurance Portability and Accountability Act (“HIPAA”). The Company’s telemedicine platform facilitates consultations between patients and licensed physicians and relies on third-party technology infrastructure and healthcare professionals operating in accordance with applicable state regulatory frameworks.
The physicians who conduct medical cannabis evaluations through the PrestoDoctor platform are independent medical professionals who are responsible for the medical services they provide to patients in accordance with applicable state laws and professional standards. The Company provides the technology platform and administrative support that facilitate these telemedicine consultations.
Although the Company holds certain cannabis-related intellectual property and may evaluate potential licensing opportunities in jurisdictions where cannabis activities are permitted under applicable state laws, the Company does not currently cultivate, distribute, or sell cannabis products.
Cannabis remains classified as a Schedule I controlled substance under the federal Controlled Substances Act (“CSA”). While a number of states have adopted laws permitting medical or adult-use cannabis activities under state regulatory frameworks, such activities remain illegal under federal law. As a result, any future activities involving cannabis-related products or licensing arrangements could be subject to regulatory uncertainty and legal risks. The Company intends to comply with applicable federal, state, and local laws in jurisdictions in which it conducts business.
The Company’s current operations consist primarily of telemedicine services conducted through the PrestoDoctor platform and do not involve the cultivation, manufacture, or sale of cannabis products.
Risk factors
As filed, 1,111 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company faces various risks including:
- dependence on telemedicine revenue
- regulatory changes affecting telemedicine or medical cannabis programs
- competition from larger telemedicine providers
- reliance on third-party physicians
- potential need for additional capital.
Regulation of Telemedicine and Physician Licensing May Affect Our Operations
The Company’s telemedicine services are subject to state laws and regulations governing the practice of medicine, telemedicine, and physician licensing. Physicians providing consultations through the PrestoDoctor platform must comply with applicable state medical licensing requirements and telemedicine regulations in the jurisdictions where patients are located. Changes in state laws, regulations, or enforcement policies related to telemedicine, medical cannabis evaluations, or physician licensing could affect the ability of physicians to provide services through the Company’s platform or increase compliance costs. Any such changes could have a material adverse effect on the Company’s business, financial condition, and results of operations.
Cybersecurity
As filed, 373 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company relies on information technology systems and third-party service providers to operate its telemedicine platform.
Management maintains processes designed to identify and manage cybersecurity risks associated with these systems.
As of the date of this report, the Company is not aware of any cybersecurity incidents that have materially affected its operations.
Properties
As filed, 183 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company maintains its principal executive office in Mesquite, Nevada as described above.
Many administrative functions are conducted remotely through virtual office arrangements.
Management's discussion and analysis
As filed, 4,389 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Overview
Dogecoin Cash Inc. operates primarily through its majority-owned subsidiary PrestoCorp, Inc., which conducts telemedicine services through the PrestoDoctor platform.
The Company generates substantially all of its revenue from telemedicine consultation services facilitated through the PrestoDoctor platform.
Digital Asset Initiatives
The Company maintains certain digital asset and blockchain-related initiatives through subsidiaries including DogeSPAC LLC, Meme Coins, Inc., and Dogecoin Treasury, Inc. These activities currently represent exploratory or strategic initiatives and do not constitute a significant source of the Company’s revenue or operating cash flows. The Company’s principal operating business remains the provision of telemedicine services through its majority-owned subsidiary PrestoCorp, Inc.
Results of Operations
Year Ended December 31, 2025 compared with the Year Ended December 31, 2024
| 2025 | Years Ended A December 31, 2024 | B December 31, | A-B Change | Change % |
|---|---|---|---|---|
| REVENUE | $738,907 | $802,704 | $(63,797) | (8)% |
| Cost of revenues | 265,704 | 310,620 | (44,916) | (14)% |
| Cost of sales % of total sales | 36% | 39% | (3)% | (7)% |
| Gross profit | 473,203 | 492,084 | (18,881) | (4)% |
| Gross profit % of sales | 64% | 61% | ||
| EXPENSES | ||||
| Professional fees | 192,806 | 309,397 | (126,591) | (40)% |
| Depreciation and amortization | 1,182 | 3,329 | (2,147) | (64)% |
| Wages and salaries | 294,328 | 364,949 | (70,621) | (19)% |
| Advertising | 3,758 | 12,268 | (8,510) | (69)% |
| General and administrative | 527,832 | 484,612 | 42,462 | 9% |
| Total expenses | 1,019,906 | 1,174,555 | (165,407) | (14)% |
| NET LOSS FROM CONTINUING OPERATIONS | (546,703) | (682,471) | 146,526 | (21)% |
Revenue for the fiscal year ended December 31, 2025 decreased 8% compared to the year ended December 31, 2024. Cost of revenues as a percentage of sales decreased 14% between the years. The reason for the decrease is there is a significant increase in competition for market share in the cannabis tele-medicine industry.
Total operating expenses decreased 14% in 2025 compared with 2024 which trended down as did revenue in the current year. Decreases in professional fees, depreciation and amortization, wages and salaries, and advertising expenses. Depreciation and amortization decreased due to patents becoming fully amortized. Advertising costs were reduced by taking a more focused approach to our target markets. PrestoDoctor salaries decreased with an effort to consolidate and reduce employees and officers reducing their salaries. Professional fees decreased due to a decrease in legal and accounting. General and administrative expenses increased due to $75,055 in bad debts and an increase in web costs.
Revenue is derived primarily from telemedicine consultation services conducted through the PrestoDoctor platform.
Operating expenses consist primarily of:
- platform development
- physician network support
- professional fees
- marketing and administrative expenses.
Liquidity and Capital Resources
Cash used in operating activities was $39,583 in 2025 compared to $107,671 in 2024. In 2025, financing activities provided $34,202 compared to $60,092 in 2024. We ended 2025 with $29,553 in cash on hand.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net loss of $10,043,831 and $1,780,240 respectively, for the years ended December 31, 2025, and 2024 and had an accumulated deficit of $84,389,964 as of December 31, 2025. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
The Company has historically funded operations through telemedicine revenues and financing transactions.
Future expansion of the Company’s operations may require additional capital.
Market risk
As filed, 122 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company qualifies as a smaller reporting company and is not required to provide the information required by this item.
Controls and procedures
As filed, 474 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management is responsible for establishing and maintaining disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed with the Securities and Exchange Commission is recorded, processed, summarized, and reported within required time periods.
Management evaluated the effectiveness of these controls as of the end of the reporting period and concluded that the Company’s disclosure controls and procedures were effective.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $738.9k | us-gaap:Revenues |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $265.7k | us-gaap:CostOfRevenue |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $473.2k | us-gaap:GrossProfit |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$546.7k | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $93.0k | us-gaap:InterestExpense |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-10-01 to 2025-12-31 | −$2.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$10.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$39.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-12-31 | $29.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $944.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $2.2m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $840.1k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $2.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | −$1.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001096906-26-000391. Last ingested by Listed: Nov 3, 2026, 21:17 ET. Listed shows no prices and gives no investment advice.